Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces

References

• Couzin-Frankel J, Breakthrough of the year 2013 Cancer immunotherapy. Science. 2013;3426165.1432–1433.
   PubMed Web of Science ®Google Scholar
• Pardoll DM, The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer. 2012;124.252–264.
   PubMed Web of Science ®Google Scholar
• Li B, Chan HL, Chen P, Immune Checkpoint Inhibitors: basics and Challenges. Current Medicinal Chemistry. 2019;2617.3009–3025.
   PubMed Web of Science ®Google Scholar
• Sznol M, Postow MA, Davies MJ et al. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management Cancer Treatment Reviews 2017 58 70–76.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM, Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;274.450‐461.
   PubMed Web of Science ®Google Scholar
• Lipson EJ, Drake CG, Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clinical Cancer Research. 2011;1722.6958–6962.
   PubMed Web of Science ®Google Scholar
• Trinh S, Le A, Gowani S, et al., Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: A Minireview of Current Clinical Guidelines. Asia-Pacific Journal of Oncology Nursing. 2019;62.154–160.
   PubMed Web of Science ®Google Scholar
• Raschi E, Mazzarella A, Antonazzo IC; et al. Toxicities with Immune Checkpoint Inhibitors: emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System. Target Oncol. 2019.142 205–221.
   PubMed Web of Science ®Google Scholar
• Ji -H-H, Tang X-W, Dong Z; et al. Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: analysis of Spontaneous Reports Submitted to FAERS. Clinical Drug Investigation. 2019.393 319–330.
   PubMed Web of Science ®Google Scholar
• Garon-Czmil J, Petitpain N, Rouby F; et al. Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the French Pharmacovigilance database. Sci Rep. 2019.91 19419.
   PubMed Web of Science ®Google Scholar
• Ali AK, Watson DE, Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies. Pharmacotherapy. 2017;3711.1383–1390.
   PubMed Web of Science ®Google Scholar
• Tan MH, Iyengar R, Mizokami-Stout K et al. Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports. Clinical Diabetes and Endocrinology.2019 51 1.
   PubMedGoogle Scholar
• Joshi MN, Whitelaw BC, Carroll PV, MECHANISMS IN ENDOCRINOLOGY: hypophysitis: diagnosis and treatment. European Journal of Endocrinology. 2018;1793.R151–R163.
   PubMed Web of Science ®Google Scholar
• Gutenberg A, Landek-Salgado MA, Tzou S-C, et al. Autoimmune hypophysitis: expanding the differential diagnosis to CTLA-4 blockade. Expert Review of Endocrinology & Metabolism. 2009; 4 681–6986.
   PubMedGoogle Scholar
• Araujo PB, Coelho MC, Arruda M, et al.Ipilimumab-induced hypophysitis: review of the literature. Journal of Endocrinological Investigation. 2015; 3 3811 1159–1166.
   PubMed Web of Science ®Google Scholar
• Chang LS, Barroso-Sousa R, Tolaney SM, et al. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev.2019;40(1):17–65.
   PubMed Web of Science ®Google Scholar
• Dillard T, Yedinak CG, Alumkal J; et al. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary. 2010.131 29–38.
   PubMed Web of Science ®Google Scholar
• Ryder M, Callahan M, Postow MA; et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocrine-Related Cancer. 2014.212 371–381.
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm Accessed Mar 2020.
   Google Scholar
• Chan KK, Bass AR, Autoimmune complications of immunotherapy: pathophysiology and management.BMJ.2020;369.m736.
   PubMedGoogle Scholar
• June CH, Warshauer JT, Bluestone JA,Is autoimmunity the Achilles’ heel of cancer immunotherapy? Nat.Med.2017;235.540–547.
   Web of Science ®Google Scholar
• Young A, Quandt Z, Bluestone JA, The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy. Cancer Immunology Research. 2018;612.1445–1452.
   PubMed Web of Science ®Google Scholar
• Heaney AP, Sumerel B, Rajalingam R; et al. HLA Markers DQ8 and DR53 Are Associated With Lymphocytic Hypophysitis and May Aid in Differential Diagnosis. The Journal of Clinical Endocrinology & Metabolism. 2015;100(11):4092–4097.
   PubMed Web of Science ®Google Scholar
• Stamatouli AM, Quandt Z, Perdigoto AL et al., Collateral Damage: insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes.2018;678 1471–1480.
   PubMed Web of Science ®Google Scholar
• Iwama S, De Remigis A, Callahan MK et al., Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Science Translational Medicine.2014;6230 230ra45.
   PubMed Web of Science ®Google Scholar
• Caturegli P, Di Dalmazi G, Lombardi M et al., Hypophysitis Secondary to Cytotoxic T-Lymphocyte–Associated Protein 4 Blockade. The American Journal of Pathology.2016;18612 3225–3235.
   PubMed Web of Science ®Google Scholar
• Javorsky BR, Aron DC, Findling JW, et al. Hypothalamus and Pituitary Gland.Greenspan’s Basic and Clinical Endocrinology. Gardner DG, Shoback D, editors. 9th ed. Mc Graw-Hill Lange; 2011. p. 65–114.
   Google Scholar
• Robinson AG The Posterior Pituitary (Neurohypophysis).Greenspan’s Basic and Clinical Endocrinology. Gardner DG, Shoback D, editors. 9th ed. Mc Graw-Hill Lange; 2011. p. 115–128.
   Google Scholar
• Mei Y, Bi WL, Greenwald NF; et al. Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget. 2016.747 76565–76576.
   PubMedGoogle Scholar
• Da Gama Duarte J, Parakh S, Andrews MC et al. Autoantibodies May Predict Immune-Related Toxicity: results from a Phase I Study of Intralesional Bacillus Calmette–Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma Frontiers in Immunology 2018;9:411.
   PubMed Web of Science ®Google Scholar
• Gowen MF, Giles KM, Simpson D; et al. Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors. Journal of Translational Medicine. 2018;16(1):82.
   PubMedGoogle Scholar
• Leiter A, Gnjatic S, Fowkes M; et al. A COMMON PITUITARY AUTOANTIBODY IN TWO PATIENTS WITH IMMUNE CHECKPOINT INHIBITOR-MEDIATED HYPOPHYSITIS: ZCCHC8. AACE Clinical Case Reports. 2020;6(4):e151–e160.
   PubMedGoogle Scholar
• Zhai Y, Ye X, Hu F, et al. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system. Journal for ImmunoTherapy of Cancer. 2019; 7 2861.
   PubMed Web of Science ®Google Scholar
• González-Rodríguez E, Rodríguez-Abreu D,Immune checkpoint inhibitors review and management of endocrine adverse events.Oncologist.2016;217.804–816.
   PubMed Web of Science ®Google Scholar
• Byun DJ, Wolchok JD, Rosenberg LM; et al. Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies. Nature Reviews Endocrinology. 2017.134 195–207.
   PubMed Web of Science ®Google Scholar
• Ferrari SM, Fallahi P, Elia G et al., Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies. International Journal of Molecular Sciences. 2019;20(10):2560.
   Web of Science ®Google Scholar
• Cukier P, Santini FC, Scaranti M; et al. Endocrine side effects of cancer immunotherapy. Endocrine-Related Cancer. 2017.2412 T331–T347.
   PubMed Web of Science ®Google Scholar
• Corsello SM, Barnabei A, Marchetti P; et al. Endocrine side effects induced by immune checkpoint inhibitors. The Journal of Clinical Endocrinology & Metabolism. 2013.984 1361–1375.
   PubMed Web of Science ®Google Scholar
• Xu H, Tan P, Zheng X et al. Immune-related adverse events following administration of anti-cytotoxic T-lymphocyte-associated protein-4 drugs: a comprehensive systematic review and meta-analysis Drug Des Devel Ther 2019 13 2215–2234.
   PubMed Web of Science ®Google Scholar
• Khoja L, Day D, Wei-Wu Chen T; et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Annals of Oncology. 2017.2810 2377–2385.
   PubMed Web of Science ®Google Scholar
• Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015; 13 2111.
   PubMedGoogle Scholar
• Costa R, Carneiro BA, Agulnik M; et al. Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. Oncotarget. 2017.85 8910–8920.
   PubMedGoogle Scholar
• Faje A, Reynolds K, Zubiri L et al., Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. European Journal of Endocrinology.2019;1813 211‐219.
   PubMed Web of Science ®Google Scholar
• de Filette J, Andreescu CE, Cools F et al., A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors. Hormone and Metabolic Research.2019;513 145–156.
   PubMed Web of Science ®Google Scholar
• Barroso-Sousa R, Barry WT, Garrido-Castro AC; et al. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. JAMA Oncology. 2018.42 173–182.
   PubMed Web of Science ®Google Scholar
• Zhang B, Wu Q, Zhou YL et al. Immune-related adverse events from combination immunotherapy in cancer patients: A comprehensive meta-analysis of randomized controlled trials. International Immunopharmacology. 2018;63 292–298.
   PubMed Web of Science ®Google Scholar
• Baxi S, Yang A, Gennarelli RL et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis BMJ 2018 360 k793.
   PubMedGoogle Scholar
• Bekki T, Takakura Y, Kochi M, et al. A Case of Isolated Adrenocorticotropic Hormone Deficiency Caused by Pembrolizumab. Case Reports in Oncology. 2020; 13 200–2061.
   PubMed Web of Science ®Google Scholar
• Keitaro Kanie K, Genzo Iguchi G, Bando H; et al. Two Cases of Atezolizumab-Induced Hypophysitis. Journal of the Endocrine Society. 2018.21 91–95.
   PubMed Web of Science ®Google Scholar
• Percik R, Shlomai G, Tirosh A; et al. Isolated autoimmune adrenocorticotropic hormone deficiency: from a rare disease to the dominant cause of adrenal insufficiency related to check point inhibitors. Autoimmunity Reviews. 2020.192 102454.
   PubMed Web of Science ®Google Scholar
• Cho KY, Miyoshi H, Nakamura A; et al. Hyponatremia can be a powerful predictor of the development of isolated ACTH deficiency associated with nivolumab treatment [Letter to the Editor]. Endocrine Journal. 2017.642 235–236.
   PubMed Web of Science ®Google Scholar
• Ohara N, Kobayashi M, Ohashi K; et al. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature. Journal of Medical Case Reports. 2019.131 88.
   PubMedGoogle Scholar
• Takeno A, Yamamoto M, Morita M; et al. Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report. BMC Endocrine Disorders. 2019.191 25.
   PubMedGoogle Scholar
• Kitajima K, Ashida K, Wada N; et al. Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab. Japanese Journal of Clinical Oncology. 2017.475 463–466.
   PubMed Web of Science ®Google Scholar
• Seki T, Yasuda A, Oki M, et al. Secondary Adrenal Insufficiency Following Nivolumab Therapy in a Patient with Metastatic Renal Cell Carcinoma. The Tokai Journal of Experimental and Clinical Medicine.2017;423.115–120.
   PubMedGoogle Scholar
• Takaya K, Sonoda M, Fuchigami A; et al. Isolated adrenocorticotropic hormone deficiency caused by nivolumab in a patient with metastatic lung cancer. Internal Medicine. 2017.5618 2463–2469.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Wu HH, Wang W, <p>A case of small-cell lung cancer with adrenocorticotropic hormone deficiency induced by nivolumab.OncoTargets and Therapy.2019;12.2181‐2186.
   Web of Science ®Google Scholar
• Zeng MF, Chen L, Ye HY, et al. Primary hypothyroidism and isolated ACTH deficiency induced by nivolumab therapy: case report and review. Medicine (Baltimore). 2017; 96 e842644.
   PubMed Web of Science ®Google Scholar
• Kastrisiou M, Kostadima F-L, Kefas A et al. Nivolumab-induced hypothyroidism and selective pituitary insufficiency in a patient with lung adenocarcinoma: a case report and review of the literature. ESMO Open.2017 24 e000217.
   PubMed Web of Science ®Google Scholar
• Takebayashi K, Ujiie A, Kubo M; et al. Isolated Adrenocorticotropic Hormone Deficiency and Severe Hypercalcemia After Destructive Thyroiditis in a Patient on Nivolumab Therapy With a Malignant Melanoma. Journal of Clinical Medicine Research. 2018;10(4):358–362.
   PubMedGoogle Scholar
• Ariyasu H, Inaba H, Ota T; et al. Thyrotoxicosis and Adrenocortical Hormone Deficiency During Immune-checkpoint Inhibitor Treatment for Malignant Melanoma. In Vivo (Athens, Greece). 2018.322 345–351.
   PubMed Web of Science ®Google Scholar
• Okano Y, Satoh T, Horiguchi K; et al. Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma. Endocrine Journal. 2016.6310 905–912.
   PubMed Web of Science ®Google Scholar
• Yamagata S, Kageyama K, Takayasu S; et al. Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer. Internal Medicine. 2019.5824 3557–3562.
   PubMed Web of Science ®Google Scholar
• Okahata S, Sakamoto K, Mitsumatsu T; et al. Fulminant type 1 diabetes associated with Isolated ACTH deficiency induced by anti-programmed cell death 1 antibody—insight into the pathogenesis of autoimmune endocrinopathy. Endocrine Journal. 2019.664 295–300.
   PubMed Web of Science ®Google Scholar
• Lupi I, Brancatella A, Cosottini M. et al. Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases. Endocrinol Diabetes Metab Case Rep. 2019;19–0102. Advance online publication
   Google Scholar
• Ascierto PA, Del Vecchio M, Robert C; et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2017;18(5):611–622.
   PubMed Web of Science ®Google Scholar
• Maker AV, Yang JC, Sherry RM; et al. Intrapatient dose escalation of Anti???CTLA-4 antibody in patients with metastatic melanoma. Journal of Immunotherapy. 2006.294 455–463.
   PubMed Web of Science ®Google Scholar
• Albarel F, Gaudy C, Castinetti F; et al. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. European Journal of Endocrinology. 2015;172(2):195–204
   PubMed Web of Science ®Google Scholar
• Faje AT, Sullivan R, Lawrence D; et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic Melanoma. The Journal of Clinical Endocrinology & Metabolism. 2014.9911 4078–4085.
   PubMed Web of Science ®Google Scholar
• Min L, Hodi FS, Giobbie-Hurder A; et al. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clinical Cancer Research. 2015:21(4):749–755.
   PubMed Web of Science ®Google Scholar
• Torino F, Barnabei A, De Vecchis L; et al. Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. The Oncologist. 2012;17(4):525–535.
   PubMed Web of Science ®Google Scholar
• Kumar M, Bowyer S, Lorigan P, et al. Ipilimumab-induced hypophysitis in melanoma patients: a single centre experience. Endocrine Abstracts. 2016 41 GP164.
   Google Scholar
• Weber JS, Hodi FS, Wolchok JD; et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. Journal of Clinical Oncology. 2017;35(7):785–792.
   PubMed Web of Science ®Google Scholar
• Scott ES, Long GV, Guminski A; et al. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. European Journal of Endocrinology. 2018;178(2):173–180
   PubMed Web of Science ®Google Scholar
• KEYTRUDA® (pembrolizumab) Prescribing Information Available from: http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf. Accessed May 2020.
   Google Scholar
• Bai X, Lin X, Zheng K; et al. Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase. Endocrine. 2020;69(3):670–681.
   PubMed Web of Science ®Google Scholar
• Castinetti F, Albarel F, Archambeaud F; et al. French endocrine society guidance on endocrine side effects of immunotherapy. Endocrine-Related Cancer. 2019;26(2):G1–G18.
   PubMed Web of Science ®Google Scholar
• Sanders LR Water Metabolism McDermott MT endocrine secrets 6th Edition [United States of America] Elsevier, Saunders; 2013. p.  198–218.
   Google Scholar
• De Sousa SMC, Sheriff N, Tran CH; et al. Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis. Pituitary. 2018;21(3):274–282.
   PubMed Web of Science ®Google Scholar
• Bellastella G, Maiorino MI, Bizzarro A; et al. Revisitation of autoimmune hypophysitis: knowledge and uncertainties on pathophysiological and clinical aspects. Pituitary. 2016;19(6)625–642.
   PubMed Web of Science ®Google Scholar
• Falorni A, Minarelli V, Bartoloni E; et al. Diagnosis and classification of autoimmune hypophysitis. Autoimmunity Reviews. 2014;13(4–5) 412‐416.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. New England Journal of Medicine. 2015;373(1):23–34.
   PubMed Web of Science ®Google Scholar
• Juszczak A, Gupta A, Karavitaki N; et al. MECHANISMS IN ENDOCRINOLOGY: ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. European Journal of Endocrinology. 2012;167(1):1–5.
   PubMed Web of Science ®Google Scholar
• Min L, Vaidya A, Becker C, Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series. Endocrine Practice. 2012;18(3):351–355.
   PubMed Web of Science ®Google Scholar
• Weber JS, Dummer R, de Pril V; et al. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013;119(9):1675–1682.
   PubMed Web of Science ®Google Scholar
• Weber JS, Kähler KC, Hauschild A, Management of immune-related adverse events and kinetics of response with ipilimumab. Journal of Clinical Oncology. 2012;30(21):2691–2697.
   PubMed Web of Science ®Google Scholar
• Caturegli P, Newschaffer C, Olivi A; et al. Autoimmune hypophysitis. Endocrine Reviews. 2005;26(5):599–614.
   PubMed Web of Science ®Google Scholar
• Mahzari M, Liu D, Arnaout A et al. Immune checkpoint inhibitor therapy associated hypophysitis Clinical Medicine Insights: Endocrinology and Diabetes 2015;8:21‐28.
   PubMed Web of Science ®Google Scholar
• Thapi S, Leiter A, Galsky M; et al. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis. Journal for ImmunoTherapy of Cancer. 2019;7(1):248.
   PubMed Web of Science ®Google Scholar
• Nallapaneni NN, Mourya R, Bhatt VR; et al. Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash. Journal of the National Comprehensive Cancer Network. 2014;12(8):1077–1081.
   PubMed Web of Science ®Google Scholar
• Zhao C, Tella SH, Del Rivero J; et al. Anti–PD-L1 treatment induced central diabetes insipidus. The Journal of Clinical Endocrinology & Metabolism. 2018;103(2):365–369.
   PubMed Web of Science ®Google Scholar
• Gunawan F, George E, Roberts A, Combination immune checkpoint inhibitor therapy nivolumab and ipilimumab associated with multiple endocrinopathies.Endocrinology, Diabetes & Metabolism Case Reports.2018;2018:17–0146.
   PubMedGoogle Scholar
• Deligiorgi MV, Siasos G, Vergadis C et al. Central diabetes insipidus related to anti-programmed cell-death 1 protein active immunotherapy International Immunopharmacology 2020;83:106427.
   PubMed Web of Science ®Google Scholar
• Andrioli M, Giraldi FP, Cavagnini F, Isolated corticotrophin deficiency.Pituitary. 2006;9(4):289–295.
   PubMedGoogle Scholar
• Haanen J, Carbonnel F, Robert C; et al. ESMO guidelines committee. management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2017.28suppl_4 iv119–iv142.
   PubMedGoogle Scholar
• Brahmer JR, Lacchetti C, Schneider BJ; et al. National comprehensive cancer network. management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline. Journal of Clinical Oncology. 2018;36(17):1714–1768.
   PubMed Web of Science ®Google Scholar
• Puzanov I, Diab A, Abdallah K; et al. Society for immunotherapy of cancer toxicity management working group. managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (sitc) toxicity management working group. Journal for ImmunoTherapy of Cancer. 2017;5(1): 95.
   PubMedGoogle Scholar
• Management of immunotherpy-Related Toxicities. National comphrehensive cancer network (NCCN) guidelines. Version 2; 2019. Available from https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf. Accessed Jul 2019
   Google Scholar
• Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab.2016;101(11):3392–3888.
   Web of Science ®Google Scholar
• Sugihara H, Review on recent topics in hypophysitis. Journal of Nippon Medical School. 2017;84(5):201‐208.
   PubMed Web of Science ®Google Scholar
• Bornstein SR, Allolio B, Arlt W; et al. Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2016.1012 364–389.
   PubMed Web of Science ®Google Scholar
• Min L, Hodi FS, Giobbie-Hurder A, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. Clin. Cancer Res. 2015;21(4):749–55.
   Google Scholar
• Molitch ME, Clemmons DR, Malozowski S, et al. Endocrine Society. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 20112011;96(6):1587–609.
   Google Scholar
• https://radiopaedia.org/articles/lymphocytic-hypophysitis. Accessed Jun 2020.
   Google Scholar
• Carpenter KJ, Murtagh RD, Lilienfeld H; et al. Ipilimumab-induced hypophysitis: MR imaging findings. American Journal of Neuroradiology. 2009;30(9):1751–1753.
   PubMed Web of Science ®Google Scholar
• Prete A, Salvatori R, Hypophysitis 2018 Aug 15 Endotext Feingold KR, Anawalt B, Boyce A et al. editors www.ncbi.nlm.nih.gov/books/NBK519842/MDText.com Inc, South Dartmouth, MA
   Google Scholar
• Girotra M, Hansen A, Farooki A; et al. Investigational drug steering committee (idsc) immunotherapy task force collaboration. the current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management. JNCI Cancer Spectrum. 2018.23 pky021.
   PubMed Web of Science ®Google Scholar
• Xu C, Ricciuti A, Caturegli P, et al. Autoimmune lymphocytic hypophysitis in association with autoimmune eye disease and sequential treatment with infliximab and rituximab. Pituitary. 2015; 18 441–4474.
   PubMed Web of Science ®Google Scholar
• Adams NC, Farrell TP, O’Shea A; et al. Neuroimaging of central diabetes insipidus—when, how and findings. Neuroradiology. 2018;60(10):995–1012.
   PubMed Web of Science ®Google Scholar
• Cacciari E, Zucchini S, Carlà G; et al. Endocrine function and morphological findings in patients with disorders of the hypothalamo-pituitary area: a study with magnetic resonance. Archives of Disease in Childhood. 1990.6511 1199–1202.
   PubMed Web of Science ®Google Scholar
• Turner HE, Wass JAH Hypothyroidism Oxford handbook of endocrinology and diabetes 2nd ed [United States of America] Oxford University Press Inc; 2009. p. 56–65.
   Google Scholar
• Meikle AW, Tyler FH, Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function. The American Journal of Medicine. 1977;63(2):200–207.
   PubMed Web of Science ®Google Scholar
• Higham CE, Olsson-Brown A, Carroll P; et al. SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr Connect. 2018;7(7): G1–G7.
   PubMed Web of Science ®Google Scholar
• Cooksley T, Girotra M, Ginex P; et al. Multinational association of supportive care in cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities. Support Care Cancer. 2020;28(12): 6175–6181.
   PubMed Web of Science ®Google Scholar
• Faje AT, Lawrence D, Flahert K et al., High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer.2018;124(18):3706–3714.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Toxicities and outcomes: do steroids matter? Cancer. 2018;12418.3638–3640.
   PubMed Web of Science ®Google Scholar
• Lammert A, Schneider HJ, Bergmann T; et al. Hypophysitis caused by ipilimumab in cancer patients: hormone replacement or immunosuppressive therapy. Experimental and Clinical Endocrinology & Diabetes. 2013.12110 581–587.
   PubMed Web of Science ®Google Scholar
• Park HJ, Ahn ST, Moon DG, Evolution of guidelines for testosterone replacement therapy. J Clin Med. 2019;83.410.
   Web of Science ®Google Scholar
• Deli T, Orosz M, Jakab A, Hormone replacement therapy in cancer survivors – review of the literature. Pathol Oncol Res. 2020;261.63–78.
   PubMed Web of Science ®Google Scholar
• D’Alonzo M, Bounous VE, Villa M, et al., Current evidence of the oncological benefit-risk profile of hormone replacement therapy. Medicina (Kaunas). 2019;559.573.
   Web of Science ®Google Scholar
• Fraietta R, Zylberstejn DS, Esteves SC, Hypogonadotropic hypogonadism revisited. Clinics (Sao Paulo). 2013;68Suppl S1.81–88.
   PubMedGoogle Scholar
• Stuenkel CA, Davis SR, Gompel A; et al. Treatment of symptoms of the menopause: an endocrine society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2015;100(11):3975–4011.
   PubMed Web of Science ®Google Scholar
• The 2017 hormone therapy position statement of The North American Menopause Society The 2017 hormone therapy position statement of the North American menopause society. Menopause . 2017. 247. 728–753.
   PubMed Web of Science ®Google Scholar
• Bhasin S, Brito JP, Cunningham GR; et al. Testosterone therapy in men with hypogonadism: an endocrine society* clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2018.1035 1715–1744.
   PubMed Web of Science ®Google Scholar
• Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline. J Endocrinol Metab.2016;10111.3888–3921.
   PubMed Web of Science ®Google Scholar
• Treatment of central diabetes insipidus. Available from http://www.uptodate.com. Accessed Feb 2019
   Google Scholar
• Curtò L, Torre ML, Cotta OR et al. Lymphocytic hypophysitis: differential diagnosis and effects of high-dose pulse steroids, followed by azathioprine, on the pituitary mass and endocrine abnormalities — report of a case and literature review ScientificWorldJournal 2010 10 126–134.
   PubMedGoogle Scholar
• Si X, Song P, Ni J, Management of immune checkpoint inhibitor-related adverse events: a review of case reports.Thoracic Cancer.2020;113.498–504.
   PubMed Web of Science ®Google Scholar
• Myers G,Immune-related adverse events of immune checkpoint inhibitors: a brief review.Current Oncology.2018;25(5):342–347.
   PubMed Web of Science ®Google Scholar
• Stelmachowska-Banaś M, Czajka-Oraniec I, Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review. Endocrine Connections. 2020;9(10):R207–R228.
   PubMed Web of Science ®Google Scholar
• El Majzoub I, Qdaisat A, Thein KZ; et al. Adverse effects of immune checkpoint therapy in cancer patients visiting the emergency department of a comprehensive cancer center. Annals of Emergency Medicine. 2019;73(1):79–87.
   PubMed Web of Science ®Google Scholar
• Cooksley T, Gupta A, Al-Sayed T, et al., Emergency presentations in patients treated with immune checkpoint inhibitors.European Journal of Cancer.2020;130.193–197.
   PubMed Web of Science ®Google Scholar
• Cooksley T, Knight T, Gupta A; et al. Emergency ambulatory outpatient management of immune-mediated hypophysitis. Supportive Care in Cancer. 2020;28(9):3995–3999.
   PubMed Web of Science ®Google Scholar
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761097s000lbl.pdf. Accessed Jun 2020
   Google Scholar
• https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_en.pdf. Accessed Jun 2020
   Google Scholar
• Migden MR, Rischin D, Schmults CD; et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. New England Journal of Medicine. 2018.3794 341–351.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Sullivan RJ, Ott PA; et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncology. 2016.22 234–240.
   PubMed Web of Science ®Google Scholar
• Menzies AM, Johnson DB, Ramanujam S; et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Annals of Oncology. 2017.282 368–376.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab N, Shah M, Lopez-Olivo MA, et al. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Annals of Internal Medicine. 2018; 168(2):121–130.
   PubMed Web of Science ®Google Scholar
• Kuo C-HS, Wang -C-C, Huang Y-C; et al. Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer. Thoracic Cancer. 2019;10(5):1158–1166.
   PubMed Web of Science ®Google Scholar
• Langer CJ, Gadgeel SM, Borghaei H; et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17(11):1497–1508.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Brahmer JR; et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non–small-cell lung cancer.Journal of Clinical Oncology. 2016.34(25):2969–2979.
   PubMed Web of Science ®Google Scholar
• Ribas A, Dummer R, Puzanov I; et al. Oncolytic virotherapy promotes intratumoral t cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2018;174(4):1031–1032.
   PubMed Web of Science ®Google Scholar
• Amin A, Lawson DH, Salama AKS, et al. Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma. Journal for ImmunoTherapy of Cancer. 2016; 4(1):44.
   PubMedGoogle Scholar
• Weiss GJ, Waypa J, Blaydorn L; et al. A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus). British Journal of Cancer. 2017;117(1):33–40.
   PubMed Web of Science ®Google Scholar
• Hodi FS, Lawrence D, Cecilia Lezcano C, Bevacizumab plus ipilimumab in patients with metastatic Melanoma. Cancer Immunology Research. 2014;2(7):632–642.
   PubMed Web of Science ®Google Scholar
• van den Eertwegh AJ, Versluis J, van den Berg HP; et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(5):509–517.
   PubMed Web of Science ®Google Scholar
• Mitsaki S, Flynn M, Gore M, et al. Development of endocrinopathy following treatment of metastatic melanoma with an immune checkpoint inhibitor is associated with better response. Endocrine Abstracts.2017;50:OC2.4.
   Google Scholar
• Downey SG, Klapper JA, Smith FO; et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clinical Cancer Research. 2007;13(22):6681–6688.
   PubMed Web of Science ®Google Scholar
• Ricciuti B, Genova C, De Giglio A; et al. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. Journal of Cancer Research and Clinical Oncology. 2019:145(2):479–485.
   PubMed Web of Science ®Google Scholar
• Indini A, Di Guardo L, Cimminiello C; et al. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. Journal of Cancer Research and Clinical Oncology. 2019;145(2) 511–521.
   PubMed Web of Science ®Google Scholar
• Rogado J, Sánchez-Torres JM, Romero-Laorden N et al. Immune-related adverse events predict the therapeutic efficacy of anti–PD-1 antibodies in cancer patients European Journal of Cancer 2019 109 21–27.
   PubMed Web of Science ®Google Scholar
• Hu W, Wang G, Wang Y; et al. Uncoupling therapeutic efficacy from immune-related adverse events in immune checkpoint blockade. iScience. 2020;23(10):101580.
   PubMed Web of Science ®Google Scholar
• Das S, Johnson DB, Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. Journal for ImmunoTherapy of Cancer. 2019;71.306.
   PubMed Web of Science ®Google Scholar
• Krashin E, Piekiełko-Witkowska A, Ellis M et al. Thyroid hormones and cancer: a comprehensive review of preclinical and clinical studies Frontiers in Endocrinology 2019 10 59.
   PubMed Web of Science ®Google Scholar
• Hercbergs A, Johnson RE, Ashur‐Fabian O; et al. Medically induced euthyroid hypothyroxinemia may extend survival in compassionate need cancer patients: an observational study. Oncologist. 2015;20(1):72–76.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Molinero A, Hercbergs A, Sarrias M; et al. Plasma 3,3’,5-Triiodo-L-thyronine [T3] level mirrors changes in tumor markers in two cases of metastatic cancer of the breast and pancreas treated with exogenous L-T3. Cancer Biomarkers. 2018.21(2):433–438.
   PubMed Web of Science ®Google Scholar
• Martins F, Sykiotis GP, Maillard M, et al. New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. The Lancet Oncology. 2019; 20(1):e54–e64
   PubMed Web of Science ®Google Scholar
• Köessler T, Olivier T, Fertani S. et al.Ipilimumab-related hypophysitis may precede severe CNS immune attack.Ann Oncol. LETTERS TO THE EDITOR 2016;27(10):P1975–1976.
   PubMed Web of Science ®Google Scholar